These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 24401995

  • 1. Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.
    Tang C, Gao H, Li X, Liu Y, Li J, Qin H, Wang W, Qu L, An J, Yang S, Liu X.
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):427-33. PubMed ID: 24401995
    [Abstract] [Full Text] [Related]

  • 2. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
    Chang CH, Lee CH, Ko JC, Chang LY, Lee MC, Wang JY, Yu CJ.
    Cancer Med; 2017 Jul; 6(7):1563-1572. PubMed ID: 28639751
    [Abstract] [Full Text] [Related]

  • 3. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [Abstract] [Full Text] [Related]

  • 4. [How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].
    Tang C, Li X, Guo W, Li J, Qin H, Wang W, Qu L, An J, Gao H, Liu X.
    Zhongguo Fei Ai Za Zhi; 2013 Jul; 16(7):345-52. PubMed ID: 23866664
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T, Mori M, Yano Y, Uchida J, Nishino K, Kaji R, Hata A, Hattori Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S, Morita S, Yokota S.
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [Abstract] [Full Text] [Related]

  • 6. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
    Watanabe S, Tanaka J, Ota T, Kondo R, Tanaka H, Kagamu H, Ichikawa K, Koshio J, Baba J, Miyabayashi T, Narita I, Yoshizawa H.
    BMC Cancer; 2011 Jan 01; 11():1. PubMed ID: 21194487
    [Abstract] [Full Text] [Related]

  • 7. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, FLAURA Investigators.
    N Engl J Med; 2018 Jan 11; 378(2):113-125. PubMed ID: 29151359
    [Abstract] [Full Text] [Related]

  • 8. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
    Zhang Q, Zhang X, Yan H, Jiang B, Xu C, Yang J, Chen Z, Su J, Wu YL, Zhou Q.
    Thorac Cancer; 2016 Nov 11; 7(6):648-654. PubMed ID: 27755835
    [Abstract] [Full Text] [Related]

  • 9. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K, Hata A, Takeshita J, Okuda C, Kaji R, Masago K, Fujita S, Katakami N.
    Cancer Chemother Pharmacol; 2015 Oct 11; 76(4):835-41. PubMed ID: 26349474
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
    Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS.
    Korean J Intern Med; 2015 Nov 11; 30(6):891-8. PubMed ID: 26552465
    [Abstract] [Full Text] [Related]

  • 11. Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance.
    Zhao ZR, Wang JF, Lin YB, Wang F, Fu S, Zhang SL, Su XD, Jiang L, Zhang YG, Shao JY, Long H.
    Med Oncol; 2014 Jan 11; 31(1):810. PubMed ID: 24338271
    [Abstract] [Full Text] [Related]

  • 12. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS, Kwon JW, Shin S, Kim HS, Kim H.
    J Clin Pharm Ther; 2015 Dec 11; 40(6):661-71. PubMed ID: 26573867
    [Abstract] [Full Text] [Related]

  • 13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.
    Cochrane Database Syst Rev; 2016 May 25; (5):CD010383. PubMed ID: 27223332
    [Abstract] [Full Text] [Related]

  • 14. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.
    Han JY, Lee KH, Kim SW, Min YJ, Cho E, Lee Y, Lee SH, Kim HY, Lee GK, Nam BH, Han H, Jung J, Lee JS.
    Cancer Res Treat; 2017 Jan 25; 49(1):10-19. PubMed ID: 27188206
    [Abstract] [Full Text] [Related]

  • 15. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
    Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu da T, Zaatar A, Osorio Sanchez JA, Vu VV, Au JS, Inoue A, Lee SM, Gebski V, Yang JC.
    J Natl Cancer Inst; 2013 May 01; 105(9):595-605. PubMed ID: 23594426
    [Abstract] [Full Text] [Related]

  • 16. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
    Martínez-Navarro EM, Rebollo J, González-Manzano R, Sureda M, Evgenyeva E, Valenzuela B, Fernández FJ, Forteza J, Brugarolas A.
    Clin Transl Oncol; 2011 Nov 01; 13(11):812-8. PubMed ID: 22082647
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study Group.
    Lung Cancer; 2014 Nov 01; 86(2):195-200. PubMed ID: 25249428
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.
    Cappuzzo F, Morabito A, Normanno N, Bidoli P, Del Conte A, Giannetta L, Montanino A, Mazzoni F, Buosi R, Burgio MA, Cerea G, Chiari R, Cortinovis D, Finocchiaro G, Foltran L, Migliorino MR, Tiseo M, Ferrari S, De Marinis F.
    Lung Cancer; 2016 Sep 01; 99():31-7. PubMed ID: 27565910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.